Spyre Therapeutics Inc.

NASDAQ: SYRE · Real-Time Price · USD
16.93
0.07 (0.42%)
At close: Aug 15, 2025, 3:59 PM
16.95
0.12%
After-hours: Aug 15, 2025, 07:36 PM EDT

Spyre Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-208.02M -338.79M -83.81M -65.8M
Depreciation & Amortization
n/a 744K 1.57M 1.58M
Stock-Based Compensation
44.83M 25.68M 7.11M 8.04M
Other Working Capital
-4.3M -5.8M -2.86M 768K
Other Non-Cash Items
10.31M 217.67M 823K 90K
Deferred Income Tax
n/a n/a -327K 548K
Change in Working Capital
-4.53M -5.21M -5.5M 1.83M
Operating Cash Flow
-157.41M -99.91M -80.14M -53.72M
Capital Expenditures
n/a n/a -38K -573K
Cash Acquisitions
n/a 3.04M n/a n/a
Purchase of Investments
-599.25M -166.8M -39.5M -133.08M
Sales Maturities Of Investments
245.97M 39.9M 96.55M 111.03M
Other Investing Acitivies
n/a 15.47M n/a n/a
Investing Cash Flow
-353.29M -108.39M 57.01M -22.62M
Debt Repayment
n/a -16K -418K -510K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
-1.43M -5.38M 222K 1.9M
Financial Cash Flow
410.91M 361.08M 42.68M 1.39M
Net Cash Flow
-99.79M 152.8M 19.44M -74.96M
Free Cash Flow
-157.41M -99.91M -80.18M -54.29M